Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1910-1915, 2000;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batalla, A.
Right arrow Articles by Coto, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batalla, A.
Right arrow Articles by Coto, E.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2000;46:1910-1915.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction

Alberto Batalla1, Ruth Alvarez2, Julián R. Reguero3, Sergio Hevia3, Gustavo Iglesias-Cubero3, Victoria Alvarez2, Arturo Cortina3, Pelayo González2, Mateo M. Celada4, Alfonso Medina4 and Eliecer Coto2,a

1 Servicio Cardiología, Hospital de Cabueñes, 33280 Gijón, Spain.

2 Laboratorio Genética Molecular-Instituto Investigación Nefrológica and
3 Servicio Cardiología, Hospital Central de Asturias, 33006 Oviedo, Spain.

4 Servicio Medicina Interna, Hospital Monte Naranco, E-33006 Oviedo, Spain.
a Author for correspondence. Fax 34-985-273657; e-mail ecoto{at}hcas.Insalud.es


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: Several studies based on different populations worldwide have described an association between cardiovascular diseases and genetic variations in the apolipoprotein E (APOE), angiotensinogen (AGT), angiotensin receptor type 1 (AT1R), and angiotensin-converting enzyme (ACE) genes. In addition, there is growing evidence of an interaction between hypercholesterolemia and the renin-angiotensin system in the risk for hypertension and atherosclerosis.

Methods: To determine whether the DNA polymorphisms in APOE ({epsilon}2, {epsilon}3, and {epsilon}4 alleles), AGT (M235T), AT1R (1166 A/C), and ACE (I/D) are associated with early onset of myocardial infarction (MI), we genotyped 220 patients and 200 controls <55 years of age. Patients and controls were males from the same homogeneous Caucasian population. Data concerning hypertension, diabetes, and tobacco consumption were recorded. The lipid profiles of patients and controls were also determined.

Results: APOE, ACE, AGT, and AT1R allele and genotype frequencies did not differ between patients and controls. None of these polymorphisms was related to the biochemical values in patients or controls. The frequency of individuals who were both APOE {epsilon}4 allele carriers and AGT-TT homozygotes was significantly higher in patients than in controls (11% vs 3.5%; P = 0.0037). In patients, the frequency of {epsilon}4 carriers was significantly higher (P <0.00001) in those who were AGT-TT (46%) than those who were AGT-MT/MM (14%). Mean cholesterol was significantly higher in AGT-TT + APOE {epsilon}34/44 patients than in the TM/MM + {epsilon}34/44 or TT + {epsilon}23/33 genotypes (P = 0.029).

Conclusions: Our data suggest a synergistic effect between the APOE and AGT polymorphisms and early MI. The increased risk could be mediated in part through higher cholesterol concentrations among individuals who are AGT-TT + APOE {epsilon}4 allele carriers.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Apolipoprotein E (ApoE)1 is a plasma protein involved in cholesterol transport. ApoE is encoded by a polymorphic gene on chromosome 19 (the APOE gene), and three alleles ({epsilon}2, {epsilon}3, and {epsilon}4) have been described. These alleles differ in the amino acids at residues 112 (Cys in {epsilon}3 and {epsilon}2, and Arg in {epsilon}4) and 158 (Arg in {epsilon}3, Cys in {epsilon}2, and Arg in {epsilon}4) (1)(2). The APOE {epsilon}4 allele is a well-recognized risk factor for Alzheimer disease, and several case-control studies have described an increased risk for coronary artery disease (CAD) among {epsilon}4 carriers, with {epsilon}44 homozygotes showing an earlier onset of the disease (3)(4)(5)(6)(7)(8)(9)(10). However, other authors have found a nonsignificantly increased or even a decreased frequency of the {epsilon}4 allele among CAD patients (11)(12). Compared with {epsilon}33 homozygotes, carriers of the {epsilon}2 and {epsilon}4 alleles showed decreased and increased LDL-cholesterol, respectively (13). The {epsilon}2 allele has also been associated with higher triglyceride concentrations (14).

DNA polymorphisms in the angiotensinogen (AGT), angiotensin receptor type 1 (AT1R), and angiotensin-converting enzyme (ACE) genes have been linked to the risk of developing cardiovascular diseases. Among these polymorphisms, the ACE insertion/deletion (I/D) and the AGT-235M/T polymorphisms have been linked with differences in ACE and angiotensin II (Ang II) concentrations in plasma. Compared with individuals with an ACE-ID/II or AGT-MM/TM genotype, ACE-DD and AGT-TT genotypes have significantly higher concentrations of ACE and angiotensin, respectively (15)(16). The ACE-DD and AGT-TT genotypes have been associated with an increased risk for CAD in some studies, but not others (17)(18)(19). Several metaanalyses have investigated the association of the ACE polymorphism with myocardial infarction (MI). Whereas some authors found evidence for an association between the DD genotype and MI, others failed to confirm this result and suggested a bias toward publishing positive associations (20)(21)(22).

There is growing evidence of an interaction between the renin-angiotensin system and hypercholesterolemia in the risk for hypertension and atherosclerosis. Hypercholesterolemia induces vascular expression of AT1R in rabbits (23)(24), and ACE inhibitors and AT1R antagonists attenuate atherogenesis in hyperlipidemic rabbits and APOE-deficient mice, an animal model of atherosclerosis (25)(26). In addition, Ang II stimulates cholesterol biosynthesis in macrophages, an effect mediated by increased expression of hydroxymethylglutaryl (HMG)-CoA reductase (27).

To determine whether variations in the APOE, AGT, AT1R, and ACE genes contribute to the risk for early MI, we genotyped 220 Spanish male MI patients and 200 healthy controls younger than 55 years. The relationships between the genotypes and several clinical and biochemical markers were also analyzed.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
patients and controls
A total of 220 male consecutive patients (mean age, 43 ± 5 years; range, 26–55 years) were evaluated during the period 1994–1999. These patients had suffered a first episode of MI, defined according to the guidelines of the WHO MONICA protocol (28). Blood was obtained from the patients during hospitalization, after a 12-h fast, and the lipid profile was determined immediately. Patients were defined as hypertensive if they had a documented history of hypertension, with a systolic blood pressure >140 mmHg. In addition, smoking histories were collected from all patients by means of a structured questionnaire. None of the patients had a familial history of hypercholesterolemia or coronary disease.

We also recruited 200 male healthy controls (hospital staff, eligible residents, and blood donors; mean age, 42 ± 6 years; range, 21–55 years), who were matched with patients for age and ethnicity. Although blood pressure was not measured in these controls, they did not have cardiovascular disease or diabetes. None of the controls was using lipid-lowering or antihypertensive drugs. All patients and controls were residents in the region of Asturias (Northern Spain; total population, 1 million) and gave their consent to participate in the study. This study was approved by the Ethical Committee of Hospital Central Asturias.

apoe genotyping
Genomic DNA (100 ng) was PCR-amplified in a final volume of 30 µL containing 30 pmol of each primer (5'-TCCAAGGAGCTGCAGGCGGCGCA-3' and 5'-ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3'), 2 mmol/L each dNTP, 2 mmol/L MgCl2, 1x Taq polymerase buffer, 100 mL/L deionized formamide, and 1 U of Taq DNA-polymerase. PCR consisted of 30 cycles of 95 °C for 30 s, 62 °C for 1 min, and 75 °C for 30 s, followed by a final extension of 5 min at 72 °C. A 20-µL aliquot of each reaction was digested with 20 U of HhaI and electrophoresed on a 4% agarose gel. Restriction digestion fragments were stained with ethidium bromide and photographed. The APOE alleles were identified as described previously (2).

agt, at1r, and ace genotyping
A C-to-T change in the AGT gene produces a polymorphism at amino acid 235 (M235T). To analyze this polymorphism, we PCR-amplified genomic DNA with primers 5'-GATGCGCACAAGGTCCTG-3' and 5'-CAGGGTGCTGTCCACACTGGCTCGC-3' (annealing at 62 °C). Reactions were digested with the restriction enzyme BstUI and electrophoresed on a 3% agarose gel. Alleles were visualized as fragments of 303 bp (allele M) and 279 bp (allele T).

The 1166 A/C polymorphism in the 3' region of the AT1R gene and the 287-bp insertion/deletion (I/D) polymorphism in the ACE gene were analyzed as described previously (29). Each DD genotype was confirmed through a second PCR with primers specific for the insertion sequence (30).

statistical analysis
Differences of allele and genotype frequencies were compared using the {chi}2 test. Odds ratios and their 95% confidence intervals were also calculated. The Student t-test was used to compare two means, and ANOVA was used when more than two groups were compared. A P value <0.05 indicated a statistically significant effect. For the statistical analysis, we used the computer program BMDP-New Systems (BMDP Statistical Software).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The clinical characteristics and lipid values of the controls and patients with early MI are summarized in Table 1 . MI was strongly associated with cigarette smoking in our population. In addition, 35% and 11% of the patients were hypertensive and diabetic, respectively.


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical characteristics and TC, HDL-cholesterol, and triglycerides in the 220 patients with MI and the 200 controls.

The APOE, AGT, AT1R, and ACE genotype frequencies are summarized in Table 2 . In our population, the APOE {epsilon}4 allele and genotype frequencies were similar between patients and controls. AGT, ACE, and AT1R allele and genotype frequencies did not differ between patients and controls. Mean biochemical values did not differ between the genotypes of each of the four polymorphisms in patients or controls (Table 2 ).


View this table:
[in this window]
[in a new window]
  		Table 2. APOE, ACE, AGT, and AT1R genotype frequencies in patients and controls, and lipid values in controls and patients (controls/patients) according to the genotype.

APOE, AGT, AT1R, and ACE allele and genotype frequencies did not differ between patients with or without diabetes, or with or without hypertension (data not shown). We analyzed a possible synergistic effect between the APOE and the AGT, AT1R, and ACE polymorphisms. The APOE genotype did not modify the risk associated with the ACE or AT1R genotypes (Table 3 ). However, the frequency of carriers of the APOE {epsilon}4 allele was significantly higher among the AGT-TT patients compared with the TM/MM patients (P <0.00001). The frequency of AGT-TT + APOE {epsilon}4 carriers was significantly higher in the overall patient group compared with controls [24 of 220 (11%) vs 7 of 200 (3.5%); P = 0.0037; Table 3 ]. Thus, {epsilon}34/44 + AGT-TT individuals would have an almost fourfold higher risk of suffering an early episode of MI (odds ratio, 3.38; 95% confidence interval, 1.5–8.17).


View this table:
[in this window]
[in a new window]
  		Table 3. Distribution of the APOE genotype according to the AGT, ACE, and AT1R genotypes in the patients, and to the AGT genotype in controls.

Mean cholesterol concentrations were significantly higher in TT + {epsilon}44/34 patients (n = 24; 2480 mg/L) compared with the TM/MM + {epsilon}44/34/24 or TT + {epsilon}33/23 genotypes (n = 196; 2160 mg/L; P = 0.029; Table 4 ). A total of 94 patients had a total cholesterol (TC) value higher than the mean value (2200 mg/L), and 14 (15%) were TT + {epsilon}34/44, compared with only 10 of the 126 (8%) with a TC value below the mean (P = 0.012). Among the controls, the mean TC value was not significantly higher in those with the TT + {epsilon}34/44/24 genotype (n = 7) compared with the other genotypes (n = 193; 2250 ± 500 vs 2040 ± 400 mg/L; P = 0.07).


View this table:
[in this window]
[in a new window]
  		Table 4. Mean cholesterol, HDL, and triglycerides in patients according to APOE + AGT genotype.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Compared with other Caucasian populations, we found a lower frequency of the APOE {epsilon}4 allele. This result is in agreement with previous reports that showed the lowest frequency for the {epsilon}4 allele in Southern European populations (31)(32)(33)(34)(35). The role of APOE genotype in the risk of CAD has been analyzed previously (4)(5)(6)(7)(8)(9)(10)(11)(12)(36)(37)(38). For the {epsilon}4 allele, a significantly increased frequency in patients compared with healthy controls has been described in some studies, but not others. These discrepancies could be partly attributable to the fact that these studies analyzed different populations worldwide and that the {epsilon}4 allele could be a risk factor when associated with other genetic or environmental factors. This allele has been associated with increased LDL-cholesterol in response to dietary fat (13)(38)(39)(40). It is thus possible that the influence of the APOE {epsilon}4 allele as a risk factor for MI is limited to populations that consume a high-fat diet.

According to previous results, AGT-235TT and ACE-DD individuals have increased plasma concentrations of angiotensin and ACE, respectively (15)(16). These genotypes have been associated with a higher CAD risk (17)(18)(19). However, only the DD genotype was associated with a slight, nonsignificant increased risk of developing early MI in our population. We had previously described a synergistic effect between the ACE-DD and AT1R-CC genotypes in the risk for early CAD (29).

We also investigated a synergistic effect between the APOE and the AGT, AT1R, and ACE polymorphisms. According to our results, the APOE {epsilon}4 allele increased the risk of suffering an episode of MI among those with an AGT-TT genotype. The frequency of AGT-TT + {epsilon}4 carriers was higher in the overall patient group compared with controls, and the frequency of APOE {epsilon}4 carriers was higher among patients who were AGT-TT compared with patients who were TM/MM. Mean cholesterol was significantly higher in patients who were AGT-TT + {epsilon}4 carriers than in patients who were {epsilon}4 carriers + TM/MM or {epsilon}33/23 + TT. Taken together, these data suggest that individuals who are {epsilon}4 carriers + AGT-TT are at an increased risk of suffering an early episode of CAD, and this effect could be related to higher cholesterol concentrations.

The published results are variable with respect to the association between polymorphisms of ACE, AGT, AT1R, and APOE with CAD, hypertension, and MI. This variability could be partly attributable to the differences in the risk factors associated with these diseases. In this way, the proportion of smokers may be one important cause for this variability. The patients in our study had MI before the age of 55, and most of them were smokers. Among older patients, lipid disorders may play a more important role. It is very likely that smoking and the associated low HDL-cholesterol concentrations are the primary causes of MI among the patients in this study. Therefore, the synergistic effects of the polymorphisms at the AGT and APOE genes are likely modulating the effects of smoking on hypertension (AGT) and cholesterol (APOE) concentrations.

The existence of a synergistic effect between the AGT and APOE genotypes is in agreement with recent findings that described an interaction between lipid metabolism and the renin-angiotensin system in cardiovascular pathophysiology. Recently, Keidar et al. (27) showed that Ang II injected intraperitoneally into APOE-deficient mice increased the atherosclerotic lesion area, and peritoneal macrophages showed an increased rate of cholesterol biosynthesis mediated by an increased expression of HMG-CoA reductase. This would lead to macrophage cholesterol accumulation and foam cell formation, a major early event in the development of atherosclerosis. The stimulatory effect of Ang II on HMG-CoA reductase concentrations and cholesterol synthesis in APOE-deficient mice was blocked by treatment with losartan, an AT1R blocker (27). Losartan also had an antiatherogenic effect in non-human primates with diet-induced hypercholesterolemia (41). Endothelial dysfunction was greatly improved in hypercholesterolemic men treated with ACE inhibitors, and a reduction in aortic cholesterol content in cholesterol-fed rabbits treated with the ACE inhibitor enalapril has been reported (42)(43). Statins down-regulate AT1R expression in hypercholesterolemic men, a fact that could in part explain the beneficial effect of these drugs (44). Patients with familial hypercholesterolemia and a DD genotype would have an increased risk of CAD (45).

Our work has several limitations, some of which are inherent to case-control studies. The study was based on MI patients from a small region, and all of the patients were male and younger than 55 years. The sample was therefore small. However, the frequencies for the four polymorphisms were in the Hardy-Weinberg equilibrium, suggesting the absence of population biases. Finally, if studies based on other populations confirm our results, genotyping of APOE and AGT polymorphisms could identify individuals at a higher risk of developing MI.


   Acknowledgments
 
This work was supported by Grant FIS 99/0924 (to E.C.). R.A. and P.G. were the recipients of fellowships from the Spanish Fondo de Investigaciones Sanitarias and Fundación Mapfre, respectively.


   Footnotes
 
1 Nonstandard abbreviations: ApoE, apolipoprotein E; CAD, coronary artery disease; AGT, angiotensinogen; AT1R, angiotensin receptor type 1; ACE, angiotensin-converting enzyme; Ang II, angiotensin II; MI, myocardial infarction; HMG, hydroxymethylglutaryl; and TC, total cholesterol.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Rall SC, Weisgraber KH, Mahley RW. Human apolipoprotein E: the complete amino acid sequence. J Biol Chem 1982;257:4171-4178.[Free Full Text]
  2. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.[Web of Science][Medline] [Order article via Infotrieve]
  3. Wilson PWF, Schaefer EJ, Larson MG, Ordovás JM. Apolipoprotein E alleles and risk of coronary disease. Arterioscler Thromb Vasc Biol 1996;16:1250-1255.[Abstract/Free Full Text]
  4. van Bockxmeer FM, Mamotte CDS. Apolipoprotein E4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-880.[Web of Science][Medline] [Order article via Infotrieve]
  5. Luc G, Bard J, Arveiler D. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM study. Arterioscler Thromb 1994;14:1412-1419.[Abstract/Free Full Text]
  6. Wilson PWF, Myers RH, Larson MG, Ordovás JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, coronary heart disease: the Framingham Offspring Study. JAMA 1994;272:1666-1671.[Abstract/Free Full Text]
  7. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265-269.[Abstract/Free Full Text]
  8. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein E {epsilon}2 and {epsilon}4 alleles in patients with ischemic heart disease. Clin Genet 1989;36:183-188.[Web of Science][Medline] [Order article via Infotrieve]
  9. Eichner JE, Kuller LH, Ferrel RE, Meilahn EN, Kamboh MI. Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. Arteriosclerosis 1990;10:379-385.[Abstract/Free Full Text]
  10. Ilveskoski E, Perola M, Lehtimäki T, Laippala P, Savolainen V, Pajarinen J, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men. Circulation 1999;100:608-613.[Abstract/Free Full Text]
  11. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem 1986;32:778-781.[Abstract/Free Full Text]
  12. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 1984;65:237-241.[Web of Science][Medline] [Order article via Infotrieve]
  13. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985;37:268-285.[Web of Science][Medline] [Order article via Infotrieve]
  14. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta analysis. J Lipid Res 1992;33:447-454.[Abstract]
  15. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt HJ. The serum angiotensin concentration and the angiotensinogen gene in white and black children. J Clin Invest 1995;95:948-953.
  16. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
  17. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600-1603.[Web of Science][Medline] [Order article via Infotrieve]
  18. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.[Medline] [Order article via Infotrieve]
  19. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706-711.[Abstract/Free Full Text]
  20. Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL. A Meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996;94:708-712.[Abstract/Free Full Text]
  21. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta analysis of small and large studies. Arterioscler Thromb Vasc Biol 2000;20:484-492.[Abstract/Free Full Text]
  22. Pfohl M, Koch M, Prescod S, Haase KK, Häring HU, Karsch KR. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. Eur Heart J 1999;20:1318-1325.[Abstract/Free Full Text]
  23. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95:473-478.[Abstract/Free Full Text]
  24. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Schölkens BA, Böhm M. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997;272:H2701-H2707.[Abstract/Free Full Text]
  25. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.[Abstract/Free Full Text]
  26. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 1997;236:622-625.[Web of Science][Medline] [Order article via Infotrieve]
  27. Keidar S, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 1999;146:249-257.[Web of Science][Medline] [Order article via Infotrieve]
  28. . WHO MONICA Project. MONICA manual, revised ed 1990 Cardiovascular Diseases Unit, WHO Geneva, Switzerland. .
  29. Alvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Alvarez V, Coto E. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 1998;40:375-379.[Abstract/Free Full Text]
  30. Shanmughan V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120-121.[Web of Science][Medline] [Order article via Infotrieve]
  31. James RW, Boemi M, Giansanti R, Fumelli P, Pometta D. Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb 1993;13:1456-1459.[Abstract/Free Full Text]
  32. Valveny N, Esteban E, Kandil M, Moral P. Apo E polymorphism in Spanish and Moroccan populations. Clin Genet 1997;51:354-356.[Web of Science][Medline] [Order article via Infotrieve]
  33. Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis 1996;121:13-21.[Web of Science][Medline] [Order article via Infotrieve]
  34. Tiret L, de Knijff P, Menzel H, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS study. Arterioscler Thromb 1994;14:1617-1624.[Abstract/Free Full Text]
  35. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Genotypes with the apolipoprotein E4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Hum Genet 1996;97:677-684.[Web of Science][Medline] [Order article via Infotrieve]
  36. Kuusisto J, Mykkänen L, Kervinen K, Kesäniemi YA, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Thromb Vasc Biol 1995;15:1280-1286.[Abstract/Free Full Text]
  37. Miettinen TA, Gylling H, Vanhanen H. Serum cholesterol response to dietary cholesterol and apolipoprotein E phenotype. Lancet 1988;2:1261.[Web of Science][Medline] [Order article via Infotrieve]
  38. Tikkanen MJ, Huttunen JK, Ehnholm C, Pietinen P. Apolipoprotein E4 homozygosity predisposes to serum cholesterol elevation during high fat diet. Arteriosclerosis 1990;10:285-288.[Abstract/Free Full Text]
  39. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993;42:895-901.[Web of Science][Medline] [Order article via Infotrieve]
  40. Ordovas JM, López-Miranda J, Pérez-Jiménez F, Rodríguez CR, Park J, Cole T. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Atherosclerosis 1995;113:157-166.[Web of Science][Medline] [Order article via Infotrieve]
  41. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000;101:1586-1593.[Abstract/Free Full Text]
  42. Libby P, Miao P, Ordovas JM, Schaefer EJ. Lipoproteins increase growth of mitogen-stimulated arterial smooth muscle cells. J Cell Physiol 1985;124:1-8.[Web of Science][Medline] [Order article via Infotrieve]
  43. Masahiro S, Naoki M, Takashi Y. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 1996;127:123-129.[Web of Science][Medline] [Order article via Infotrieve]
  44. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.[Abstract/Free Full Text]
  45. O’Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 1998;97:1780-1783.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
 Arch Intern MedHome page
E. Zintzaras, G. Raman, G. Kitsios, and J. Lau
Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphic Variant as a Marker of Coronary Artery Disease: A Meta-analysis
Arch Intern Med, May 26, 2008; 168(10): 1077 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. M. Bennet, E. Di Angelantonio, Z. Ye, F. Wensley, A. Dahlin, A. Ahlbom, B. Keavney, R. Collins, B. Wiman, U. de Faire, et al.
Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk
JAMA, September 19, 2007; 298(11): 1300 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M.-Q. Xu, Z. Ye, F. B. Hu, and L. He
Quantitative Assessment of the Effect of Angiotensinogen Gene Polymorphisms on the Risk of Coronary Heart Disease
Circulation, September 18, 2007; 116(12): 1356 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. E. Ntzani, E. C. Rizos, and J. P. A. Ioannidis
Genetic Effects versus Bias for Candidate Polymorphisms in Myocardial Infarction: Case Study and Overview of Large-Scale Evidence
Am. J. Epidemiol., May 1, 2007; 165(9): 973 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
C. Sekuri, F S. Cam, E. Ercan, I. Tengiz, A. Sagcan, E. Eser, A. Berdeli, and M. Akin
Renin-angiotensin system gene polymorphisms and premature coronary heart disease
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 38 - 42.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
Y. Song, M. J. Stampfer, and S. Liu
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Ann Intern Med, July 20, 2004; 141(2): 137 - 147.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau
Genetic Markers: Progress and Potential for Cardiovascular Disease
Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. S. Jacoby and D. J. Rader
Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment
Arch Intern Med, May 26, 2003; 163(10): 1155 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
G. Kolovou, D. Daskalova, and D. P. Mikhailidis
Apolipoprotein E Polymorphism and Atherosclerosis
Angiology, January 1, 2003; 54(1): 59 - 71.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
F. Somogyvari, Z. Szolnoki, J. Marki-Zay, and L. Fodor
Real-Time PCR Assay with Fluorescent Hybridization Probes for Exact and Rapid Genotyping of the Angiotensin-converting Enzyme Gene Insertion/Deletion Polymorphism
Clin. Chem., September 1, 2001; 47(9): 1728 - 1729.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batalla, A.
Right arrow Articles by Coto, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batalla, A.
Right arrow Articles by Coto, E.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS